<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00105456</url>
  </required_header>
  <id_info>
    <org_study_id>H2757n</org_study_id>
    <nct_id>NCT00105456</nct_id>
  </id_info>
  <brief_title>A Study of Patients With HER2-Positive Metastatic Breast Cancer</brief_title>
  <official_title>registHER: An Observational Cohort Study of Patients With HER2 Positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a prospective observational cohort study designed to describe effectiveness and
      safety (treatment outcomes and clinically significant cardiac adverse events, respectively)
      in patients with HER2-positive metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>1000</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from managed care organizations, community physicians or practices, and academic
        centers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent document (unless the IRB has granted a waiver of consent)

          -  Signed Authorization for the Use and Disclosure of Health Information document

          -  HER2-positive breast cancer

          -  Initial diagnosis of metastatic (Stage IV) breast cancer within 6 months prior to
             enrollment

          -  Availability of cancer-specific historical data points in the patient's medical
             records

        Exclusion Criteria:

          -  There are no exclusion criteria for participation in this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isaiah Dimery, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2005</study_first_submitted>
  <study_first_submitted_qc>March 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2005</study_first_posted>
  <last_update_submitted>May 4, 2010</last_update_submitted>
  <last_update_submitted_qc>May 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Clinical Trials Posting Group</name_title>
    <organization>Genentech, Inc.</organization>
  </responsible_party>
  <keyword>HER2-Positive Metastatic Breast Cancer</keyword>
  <keyword>HER2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

